{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:27:05Z","timestamp":1772166425528,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005111","name":"Rigshospitalet","doi-asserted-by":"publisher","award":["E-22670-08"],"award-info":[{"award-number":["E-22670-08"]}],"id":[{"id":"10.13039\/501100005111","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Royal Library, Copenhagen University Library"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inflammation in ST-segment elevation myocardial infarction (STEMI) is an important contributor to both acute myocardial ischemia and reperfusion injury after primary percutaneous coronary intervention (PCI). Methylprednisolone is a glucocorticoid with potent anti-inflammatory properties with an acute effect and is used as an effective and safe treatment of a wide range of acute diseases. The trial aims to investigate the cardioprotective effects of pulse-dose methylprednisolone administered in the pre-hospital setting in patients with STEMI transferred for primary PCI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This trial is a randomized, blinded, placebo-controlled prospective clinical phase II trial. Inclusion will continue until 378 patients with STEMI have been evaluated for the primary endpoint. Patients will be randomized 1:1 to a bolus of 250\u00a0mg methylprednisolone intravenous or matching placebo over a period of 5\u00a0min in the pre-hospital setting. All patients with STEMI transferred for primary PCI at Rigshospitalet, Copenhagen University Hospital, Denmark, will be screened for eligibility. The main eligibility criteria are age\u2009\u2265\u200918\u00a0years, acute onset of chest pain with\u2009&lt;\u200912\u00a0h duration, STEMI on electrocardiogram, no known allergy to glucocorticoids or no previous coronary artery bypass grafting, previous acute myocardial infarction in assumed culprit, or a history with previous maniac\/psychotic episodes. Primary outcome is final infarct size measured by late gadolinium enhancement on cardiac magnetic resonance (CMR) 3\u00a0months after STEMI. Secondary outcomes comprise key CMR efficacy parameters, clinical endpoints at 3\u00a0months, the peak of cardiac biomarkers, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>We hypothesize that pulse-dose methylprednisolone administrated in the pre-hospital setting decreases inflammation and thus reduces final infarct size in patients with STEMI treated with primary PCI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>EU-CT number: 2022\u2013500762-10\u201300; Submitted May 5, 2022. ClinicalTrials.gov Identifier: NCT05462730; Submitted July 7, 2022, first posted July 18, 2022.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-023-07830-y","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T09:02:32Z","timestamp":1702630952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pre-hospital pulse glucocorticoid therapy in patients with ST-segment elevation myocardial infarction transferred for primary percutaneous coronary intervention: a randomized controlled trial (PULSE-MI)"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2299-7377","authenticated-orcid":false,"given":"Jasmine Melissa","family":"Madsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laust Emil Roelsgaard","family":"Obling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Rytoft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrik","family":"Folke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Hassager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars Bredevang","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Vejlstrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lia Evi","family":"Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Engstr\u00f8m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob Thomsen","family":"L\u00f8nborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"key":"7830_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41572-019-0090-3","volume":"5","author":"B Vogel","year":"2019","unstructured":"Vogel B, et al. ST-segment elevation myocardial infarction. Nat Rev Dis Primer. 2019;5:39.","journal-title":"Nat Rev Dis Primer"},{"key":"7830_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0140-6736(03)12113-7","volume":"361","author":"EC Keeley","year":"2003","unstructured":"Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet Lond Engl. 2003;361:13\u201320.","journal-title":"Lancet Lond Engl"},{"key":"7830_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119\u201377.","journal-title":"Eur Heart J"},{"key":"7830_CR4","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJM199912233412601","volume":"341","author":"CL Grines","year":"1999","unstructured":"Grines CL, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1999;341:1949\u201356.","journal-title":"N Engl J Med"},{"key":"7830_CR5","doi-asserted-by":"publisher","unstructured":"Nepper-Christensen, L. et al. Clinical outcome following late reperfusion with percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Eur. Heart J. Acute Cardiovasc. Care 2048872619886312 (2020) https:\/\/doi.org\/10.1177\/2048872619886312.","DOI":"10.1177\/2048872619886312"},{"key":"7830_CR6","first-page":"774","volume":"38","author":"G Heusch","year":"2017","unstructured":"Heusch G, Gersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. Eur Heart J. 2017;38:774\u201384.","journal-title":"Eur Heart J"},{"key":"7830_CR7","first-page":"935","volume":"38","author":"DJ Hausenloy","year":"2017","unstructured":"Hausenloy DJ, et al. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. Eur Heart J. 2017;38:935\u201341.","journal-title":"Eur Heart J"},{"key":"7830_CR8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/ehjci\/jes271","volume":"14","author":"J L\u00f8nborg","year":"2013","unstructured":"L\u00f8nborg J, et al. Final infarct size measured by cardiovascular magnetic resonance in patients with ST elevation myocardial infarction predicts long-term clinical outcome: an observational study. Eur Heart J Cardiovasc Imaging. 2013;14:387\u201395.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"7830_CR9","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/S0140-6736(16)30072-1","volume":"387","author":"H Kelb\u00e6k","year":"2016","unstructured":"Kelb\u00e6k H, et al. Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial. Lancet Lond Engl. 2016;387:2199\u2013206.","journal-title":"Lancet Lond Engl"},{"key":"7830_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.pharmthera.2018.01.001","volume":"186","author":"S-B Ong","year":"2018","unstructured":"Ong S-B, et al. Inflammation following acute myocardial infarction: multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol Ther. 2018;186:73\u201387.","journal-title":"Pharmacol Ther"},{"key":"7830_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nri.2017.1","volume":"17","author":"DW Cain","year":"2017","unstructured":"Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17:233\u201347.","journal-title":"Nat Rev Immunol"},{"key":"7830_CR12","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S0002-9149(03)00148-6","volume":"91","author":"GR Giugliano","year":"2003","unstructured":"Giugliano GR, Giugliano RP, Gibson CM, Kuntz RE. Meta-analysis of corticosteroid treatment in acute myocardial infarction. Am J Cardiol. 2003;91:1055\u20139.","journal-title":"Am J Cardiol"},{"key":"7830_CR13","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00424-012-1155-2","volume":"464","author":"SR Lee","year":"2012","unstructured":"Lee SR, et al. Non-genomic effect of glucocorticoids on cardiovascular system. Pflugers Arch. 2012;464:549\u201359.","journal-title":"Pflugers Arch"},{"key":"7830_CR14","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3390\/cells8101227","volume":"8","author":"B Liu","year":"2019","unstructured":"Liu B, Zhang T-N, Knight JK, Goodwin JE. The glucocorticoid receptor in cardiovascular health and disease. Cells. 2019;8:1227.","journal-title":"Cells"},{"key":"7830_CR15","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/j.jacc.2014.01.014","volume":"63","author":"IM Seropian","year":"2014","unstructured":"Seropian IM, Toldo S, Van Tassell BW, Abbate A. Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. J Am Coll Cardiol. 2014;63:1593\u2013603.","journal-title":"J Am Coll Cardiol"},{"key":"7830_CR16","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/bph.14155","volume":"175","author":"S Huang","year":"2018","unstructured":"Huang S, Frangogiannis NG. Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges. Br J Pharmacol. 2018;175:1377\u2013400.","journal-title":"Br J Pharmacol"},{"key":"7830_CR17","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","volume":"72","author":"K Thygesen","year":"2018","unstructured":"Thygesen K, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018;72:2231\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"105","key":"7830_CR18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/archsurg.1972.04180080084014","volume":"1960","author":"JG Turcotte","year":"1972","unstructured":"Turcotte JG, Feduska NJ, Carpenter EW, McDonald FD, Bacon GE. Rejection crises in human renal transplant recipients: control with high dose methylprednisolone therapy. Arch Surg Chic Ill. 1972;1960(105):230\u20136.","journal-title":"Arch Surg Chic Ill"},{"key":"7830_CR19","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1136\/ard.61.8.718","volume":"61","author":"F Buttgereit","year":"2002","unstructured":"Buttgereit F, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61:718\u201322.","journal-title":"Ann Rheum Dis"},{"key":"7830_CR20","first-page":"1057","volume":"75","author":"A Sinha","year":"2008","unstructured":"Sinha A, Bagga A. Pulse steroid therapy. Indian. J Pediatr. 2008;75:1057\u201366.","journal-title":"J Pediatr"},{"key":"7830_CR21","doi-asserted-by":"publisher","first-page":"622225","DOI":"10.3389\/fmed.2021.622225","volume":"8","author":"JM Mej\u00eda-Vilet","year":"2021","unstructured":"Mej\u00eda-Vilet JM, Ayoub I. The use of glucocorticoids in lupus nephritis: new pathways for an old drug. Front Med. 2021;8:622225.","journal-title":"Front Med"},{"key":"7830_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.semarthrit.2019.03.010","volume":"49","author":"J Deng","year":"2019","unstructured":"Deng J, Chalhoub NE, Sherwin CM, Li C, Brunner HI. Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum. 2019;49:251\u20139.","journal-title":"Semin Arthritis Rheum"},{"key":"7830_CR23","unstructured":"Pfizer. Solu-Medrol (Danish Summary Product Characteristics). (2021)."},{"key":"7830_CR24","first-page":"18","volume":"25","author":"ER Jenista","year":"2023","unstructured":"Jenista ER, et al. Revisiting how we perform late gadolinium enhancement CMR: insights gleaned over 25 years of clinical practice. J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson. 2023;25:18.","journal-title":"J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson"},{"key":"7830_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/ehjci\/jey106","volume":"20","author":"C G\u00f6ransson","year":"2019","unstructured":"G\u00f6ransson C, et al. Assessment of the myocardial area at risk: comparing T2-weighted cardiovascular magnetic resonance imaging with contrast-enhanced cine (CE-SSFP) imaging-a DANAMI3 substudy. Eur Heart J Cardiovasc Imaging. 2019;20:361\u20136.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"7830_CR26","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s10554-019-01569-x","volume":"35","author":"ESS Hansen","year":"2019","unstructured":"Hansen ESS, Pedersen SF, Pedersen SB, B\u00f8tker HE, Kim WY. Validation of contrast enhanced cine steady-state free precession and T2-weighted CMR for assessment of ischemic myocardial area-at-risk in the presence of reperfusion injury. Int J Cardiovasc Imaging. 2019;35:1039\u201345.","journal-title":"Int J Cardiovasc Imaging"},{"key":"7830_CR27","first-page":"25","volume":"12","author":"P S\u00f6rensson","year":"2010","unstructured":"S\u00f6rensson P, et al. Assessment of myocardium at risk with contrast enhanced steady-state free precession cine cardiovascular magnetic resonance compared to single-photon emission computed tomography. J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson. 2010;12:25.","journal-title":"J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson"},{"key":"7830_CR28","first-page":"481","volume":"7","author":"O Bondarenko","year":"2005","unstructured":"Bondarenko O, et al. Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson. 2005;7:481\u20135.","journal-title":"J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson"},{"key":"7830_CR29","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jcmg.2014.05.010","volume":"7","author":"M van Kranenburg","year":"2014","unstructured":"van Kranenburg M, et al. Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients. JACC Cardiovasc Imaging. 2014;7:930\u20139.","journal-title":"JACC Cardiovasc Imaging"},{"key":"7830_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jacc.2021.10.034","volume":"79","author":"T Liu","year":"2022","unstructured":"Liu T, et al. Intramyocardial hemorrhage and the \u2018Wave Front\u2019 of reperfusion injury compromising myocardial salvage. J Am Coll Cardiol. 2022;79:35\u201348.","journal-title":"J Am Coll Cardiol"},{"key":"7830_CR31","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1007\/s00330-014-3318-3","volume":"24","author":"D Kandler","year":"2014","unstructured":"Kandler D, et al. The relation between hypointense core, microvascular obstruction and intramyocardial haemorrhage in acute reperfused myocardial infarction assessed by cardiac magnetic resonance imaging. Eur Radiol. 2014;24:3277\u201388.","journal-title":"Eur Radiol"},{"key":"7830_CR32","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1148\/radiol.2503081154","volume":"250","author":"DP O\u2019Regan","year":"2009","unstructured":"O\u2019Regan DP, et al. Reperfusion hemorrhage following acute myocardial infarction: assessment with T2* mapping and effect on measuring the area at risk. Radiology. 2009;250:916\u201322.","journal-title":"Radiology"},{"key":"7830_CR33","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1016\/j.jacc.2017.03.601","volume":"69","author":"J L\u00f8nborg","year":"2017","unstructured":"L\u00f8nborg J, et al. Myocardial damage in patients with deferred stenting after STEMI: a DANAMI-3-DEFER substudy. J Am Coll Cardiol. 2017;69:2794\u2013804.","journal-title":"J Am Coll Cardiol"},{"key":"7830_CR34","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jcin.2019.01.248","volume":"12","author":"K Kyhl","year":"2019","unstructured":"Kyhl K, et al. Complete revascularization versus culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease: a DANAMI-3-PRIMULTI cardiac magnetic resonance substudy. JACC Cardiovasc Interv. 2019;12:721\u201330.","journal-title":"JACC Cardiovasc Interv"},{"key":"7830_CR35","doi-asserted-by":"publisher","first-page":"700","DOI":"10.4244\/EIJ-D-17-00857","volume":"14","author":"L Nepper-Christensen","year":"2018","unstructured":"Nepper-Christensen L, et al. Impact of diagnostic ECG-to-wire delay in STEMI patients treated with primary PCI: a DANAMI-3 substudy. EuroIntervention. 2018;14:700\u20137.","journal-title":"EuroIntervention"},{"key":"7830_CR36","doi-asserted-by":"publisher","first-page":"e004823","DOI":"10.1161\/JAHA.116.004823","volume":"6","author":"L Nepper-Christensen","year":"2017","unstructured":"Nepper-Christensen L, et al. Left ventricular hypertrophy is associated with increased infarct size and decreased myocardial salvage in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Am Heart Assoc. 2017;6:e004823.","journal-title":"J Am Heart Assoc"},{"key":"7830_CR37","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/j.jcmg.2019.01.032","volume":"12","author":"K Ekstr\u00f6m","year":"2019","unstructured":"Ekstr\u00f6m K, et al. Impact of multiple myocardial scars detected by CMR in patients following STEMI. JACC Cardiovasc Imaging. 2019;12:2168\u201378.","journal-title":"JACC Cardiovasc Imaging"},{"key":"7830_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ijcard.2020.05.011","volume":"314","author":"M Sabbah","year":"2020","unstructured":"Sabbah M, et al. Infarct size following loading with Ticagrelor\/Prasugrel versus Clopidogrel in ST-segment elevation myocardial infarction. Int J Cardiol. 2020;314:7\u201312.","journal-title":"Int J Cardiol"},{"key":"7830_CR39","doi-asserted-by":"publisher","first-page":"e001399","DOI":"10.1161\/JAHA.114.001399","volume":"4","author":"R Jabbari","year":"2015","unstructured":"Jabbari R, et al. Incidence and risk factors of ventricular fibrillation before primary angioplasty in patients with first ST-elevation myocardial infarction: a nationwide study in Denmark. J Am Heart Assoc. 2015;4:e001399.","journal-title":"J Am Heart Assoc"},{"key":"7830_CR40","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/cvr\/cvz301","volume":"116","author":"LSF Konijnenberg","year":"2020","unstructured":"Konijnenberg LSF, et al. Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction. Cardiovasc Res. 2020;116:787\u2013805.","journal-title":"Cardiovasc Res"},{"key":"7830_CR41","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1161\/01.CIR.0000017199.09457.3D","volume":"105","author":"NHJ Pijls","year":"2002","unstructured":"Pijls NHJ, et al. Coronary thermodilution to assess flow reserve: validation in humans. Circulation. 2002;105:2482\u20136.","journal-title":"Circulation"},{"key":"7830_CR42","doi-asserted-by":"publisher","first-page":"e005361","DOI":"10.1161\/CIRCINTERVENTIONS.117.005361","volume":"10","author":"WF Fearon","year":"2017","unstructured":"Fearon WF, Kobayashi Y. Invasive assessment of the coronary microvasculature: the index of microcirculatory resistance. Circ Cardiovasc Interv. 2017;10:e005361.","journal-title":"Circ Cardiovasc Interv"},{"key":"7830_CR43","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3390\/jcm9010086","volume":"9","author":"J-RD Clarke","year":"2019","unstructured":"Clarke J-RD, Kennedy R, Duarte Lau F, Lancaster GI, Zarich SW. Invasive evaluation of the microvasculature in acute myocardial infarction: coronary flow reserve versus the index of microcirculatory resistance. J Clin Med. 2019;9:86.","journal-title":"J Clin Med"},{"key":"7830_CR44","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/j.jcmg.2021.02.023","volume":"14","author":"R Scarsini","year":"2021","unstructured":"Scarsini R, et al. Coronary microvascular dysfunction assessed by pressure wire and CMR after STEMI predicts long-term outcomes. JACC Cardiovasc Imaging. 2021;14:1948\u201359.","journal-title":"JACC Cardiovasc Imaging"},{"key":"7830_CR45","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1161\/CIRCINTERVENTIONS.122.012081","volume":"15","author":"A Demirkiran","year":"2022","unstructured":"Demirkiran A, et al. The dynamic relationship between invasive microvascular function and microvascular injury indicators, and their association with left ventricular function and infarct size at 1-month after reperfused ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2022;15:892\u2013902.","journal-title":"Circ Cardiovasc Interv"},{"key":"7830_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11886-021-01442-1","volume":"23","author":"DJ Doherty","year":"2021","unstructured":"Doherty DJ, Sykes R, Mangion K, Berry C. Predictors of microvascular reperfusion after myocardial infarction. Curr Cardiol Rep. 2021;23:21.","journal-title":"Curr Cardiol Rep"},{"key":"7830_CR47","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1148\/radiol.2021204265","volume":"301","author":"CWH Beijnink","year":"2021","unstructured":"Beijnink CWH, et al. Cardiac MRI to visualize myocardial damage after ST-segment elevation myocardial infarction: a review of its histologic validation. Radiology. 2021;301:4\u201318.","journal-title":"Radiology"},{"key":"7830_CR48","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/2048872615568965","volume":"5","author":"IM Seropian","year":"2016","unstructured":"Seropian IM, Sonnino C, Van Tassell BW, Biasucci LM, Abbate A. Inflammatory markers in ST-elevation acute myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2016;5:382\u201395.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"7830_CR49","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/j.jacc.2016.01.073","volume":"67","author":"PC Westman","year":"2016","unstructured":"Westman PC, et al. Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol. 2016;67:2050\u201360.","journal-title":"J Am Coll Cardiol"},{"key":"7830_CR50","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejim.2019.03.001","volume":"64","author":"C Tiller","year":"2019","unstructured":"Tiller C, et al. Biomarker assessment for early infarct size estimation in ST-elevation myocardial infarction. Eur J Intern Med. 2019;64:57\u201362.","journal-title":"Eur J Intern Med"},{"key":"7830_CR51","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group, et al. Dexamethasone in hospitalized patients with COVID-19. Engl J Med. 2021;384:693\u2013704.","journal-title":"Engl. J. Med"},{"key":"7830_CR52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215145","author":"P-F Dequin","year":"2023","unstructured":"Dequin P-F, et al. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med. 2023. https:\/\/doi.org\/10.1056\/NEJMoa2215145.","journal-title":"N Engl J Med"},{"key":"7830_CR53","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1161\/01.CIR.57.1.56","volume":"57","author":"RA Kloner","year":"1978","unstructured":"Kloner RA, Fishbein MC, Lew H, Maroko PR, Braunwald E. Mummification of the infarcted myocardium by high dose corticosteroids. Circulation. 1978;57:56\u201363.","journal-title":"Circulation"},{"key":"7830_CR54","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1161\/01.CIR.68.2.446","volume":"68","author":"H Hammerman","year":"1983","unstructured":"Hammerman H, Kloner RA, Hale S, Schoen FJ, Braunwald E. Dose-dependent effects of short-term methylprednisolone on myocardial infarct extent, scar formation, and ventricular function. Circulation. 1983;68:446\u201352.","journal-title":"Circulation"},{"key":"7830_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2016.01.062","volume":"76","author":"A Caplan","year":"2017","unstructured":"Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: a review of glucocorticoid pharmacology and bone health. J Am Acad Dermatol. 2017;76:1\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"7830_CR56","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.semarthrit.2019.11.006","volume":"50","author":"Y Edel","year":"2020","unstructured":"Edel Y, et al. The safety of pulse corticosteroid therapy-systematic review and meta-analysis. Semin Arthritis Rheum. 2020;50:534\u201345.","journal-title":"Semin Arthritis Rheum"},{"key":"7830_CR57","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/ane.12519","volume":"133","author":"R Press","year":"2016","unstructured":"Press R, Hiew FL, Rajabally YA. Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: evidence base and clinical practice. Acta Neurol Scand. 2016;133:228\u201338.","journal-title":"Acta Neurol Scand"},{"key":"7830_CR58","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1161\/CIRCINTERVENTIONS.112.968388","volume":"5","author":"J L\u00f8nborg","year":"2012","unstructured":"L\u00f8nborg J, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv. 2012;5:288\u201395.","journal-title":"Circ Cardiovasc Interv"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07830-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07830-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07830-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T10:06:42Z","timestamp":1702634802000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07830-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7830"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07830-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3099951\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"assertion":[{"value":"23 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prior to initiation of the trial, the trial was submitted to the Clinical Trials Information System (CTIS) and approved (EU-CT number: 2022\u2013500762-10\u201300), and it was also submitted to the Danish Data Protection Agency (ID: P-2022\u2013280). The trial is conducted in compliance with the published trial protocol, the Helsinki Declaration, the GCP guidelines (ICH-GCP), and European and national laws. Furthermore, the trial is monitored by the GCP unit of Copenhagen.Due to the acute nature of STEMI and the temporary inability of the patient to provide informed consent in the pre-hospital setting, enrollment and intervention will occur in the pre-hospital setting prior to informed consent. The patient will provide informed consent as soon as possible following the acute initial treatment (primary PCI), once the patient is stable. The informed consent form (ICF) will be filled out and signed by the patient in the encrypted database program REDCap. In patients with STEMI unable to provide informed consent following primary PCI, consent will be obtained by an independent legally designated representative who will sign the ICF. The legally designated representative consent will be followed by informed consent and signature of the ICF by the patient, once the patient is stable and able to provide consent. If the patient remains unable to provide informed consent 3\u00a0days following admission, the closest relative to the patient and a legally designated representative will provide consent on behalf of the patient and sign the ICF as soon as possible. The patient will subsequently provide informed consent as soon as possible.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"All consents from the relevant parties (patients, next of kin, legal designated representative) are available upon request. All consent forms have been approved by the authorities prior to initiation of the trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"808"}}